LLY - ELI LILLY & Co
826.07
0.290 0.035%
Share volume: 3,550,713
Last Updated: Tue 04 Feb 2025 10:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.24%
PREVIOUS CLOSE
CHG
CHG%
$825.78
15.64
0.02%
Fundamental analysis
76%
Profitability
100%
Dept financing
34%
Liquidity
52%
Performance
68%
Performance
5 Days
1.85%
1 Month
7.97%
3 Months
2.48%
6 Months
6.55%
1 Year
16.62%
2 Year
144.65%
Key data
Stock price
$826.07
DAY RANGE
$805.94 - $829.04
52 WEEK RANGE
$711.40 - $972.53
52 WEEK CHANGE
$13.51
DIVIDEND
$1.30
EX-DIVIDEND DATE
08/15/2024
NEXT EARNINGS DATE
N/A
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news